Alladapt gets $100M+ to see its all-in-one oral immunotherapy allergy drug through clinical trials

Most food allergy care involves avoidance — checking ingredient labels, no peanut tables in schools, and so on. However, that paradigm has been shifting with oral immunotherapies, or OITs for short, in which patients purposely eat a bit of their allergen in the form of a modified protein in hopes...

Click to view original post